There was some marginally better news from UK public borrowing numbers. While slightly above forecasts for May, the ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

LONDON, April 14 (Reuters ... whose biotech fund holds shares in Vertex (VRTX.O), opens new tab and Ascendis Pharma . "The future cash flows of the businesses that are used to value stocks ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday.